

## DAFTAR PUSTAKA

- Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., et al., 2015. IFN- $\gamma$  from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. *Br. J. Cancer* 112: 1501–1509. doi:10.1038/bjc.2015.101
- AD, S., PL, H., A, R., S, B., JJ, R., CV, S., et al., 2001. Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer. *Gynecol. Obstet. Investig.* 7199: 254–261.
- Aggarwal, B.B., 2003. Signalling Pathways of The TNF Superfamily: A Double-Edged Sword. *Nat. Rev. Immunol.* 3: 745–756. doi:10.1038/nri1184
- Ahmed, N., & Stenvers, K.L., 2013. Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research. *Front. Oncol.* 3: 1–12. doi:10.3389/fonc.2013.00256
- Alberts, D.S., Marth, C., Alvarez, R.D., Johnson, G., Bidzinski, M., Kardatzke, D.R., et al., 2008. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of prog. *Gynecol. Oncol.* 109: 174–181. doi:10.1016/j.ygyno.2008.01.005
- Antony, M.L., Nair, R., Sebastian, P., & Karunakaran, D., 2010. Changes in expression, and/or mutations in TGF- $\beta$  receptors (TGF- $\beta$  RI and TGF- $\beta$  RII) and Smad 4 in human ovarian tumors. *J. Cancer Res. Clin. Oncol.* 136: 351–361. doi:10.1007/s00432-009-0703-4
- Asschert, J.G.W., Vellenga, E., Rutgers, M.H.J., & De Vries, E.G.E., 1999. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. *Int. J. Cancer* 82: 244–249. doi:10.1002/(SICI)1097-0215(19990719)82:2<244::AID-IJC15>3.0.CO;2-N
- Baert, T., Timmerman, D., Vergote, I., & Coosemans, A., 2015. Immunological

parameters as a new lead in the diagnosis of ovarian cancer. *Facts, views Vis. ObGyn* 7: 67–72.

- Bamias, A., Gavalas, N.G., Karadimou, A., & Dimopoulos, M.A., 2010. Immune response in ovarian cancer: How is the immune system involved in prognosis and therapy: Potential for treatment utilization. *Clin. Dev. Immunol.* doi:10.1155/2010/791603
- Bamias, A., Koutsoukou, V., Terpos, E., Tsiatas, M.L., Liakos, C., Tsitsilonis, O., et al., 2008. Correlation of NK T-like CD3+CD56+ Cells and CD4+CD25+(hi) Regulatory T Cells with VEGF and TNF $\alpha$  in Ascites from Advanced Ovarian Cancer: Association with Platinum Resistance and Prognosis in Patients Receiving First-Line, Platinum-Based chemotherapy. *Gynecol. Oncol.* 108: 421–427. doi:10.1016/j.ygyno.2007.10.018
- Batchu, R., Gruzdyn, O., Kolli, B., Dachepalli, R., Umar, P., Rai, S., et al., 2021. IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer, *Advances in Experimental Medicine and Biology*.
- Berek, J.S., Kehoe, S.T., Kumar, L., & Friedlander, M., 2018. Cancer of the ovary, fallopian tube, and peritoneum. *Int. J. Gynecol. Obstet.* 143: 59–78. doi:10.1002/ijgo.12614
- Bhatla, N., & Jones, A., 2018. The World Ovarian Cancer Coalition Atlas, World Ovarian Cancer Coalition 2018.
- Bonneau, C., Rouzier, R., Geyl, C., Cortez, A., Castela, M., Lis, R., et al., 2015. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. *Gynecol. Oncol.* 136: 112–120. doi:10.1016/j.ygyno.2014.10.024
- Bridget, C., Goode, E.L., Kalli, K.R., Knutson, K.L., & DeRycke, M.S., 2013. The immune system in the pathogenesis of ovarian cancer. *Crit. Rev. Immunol.* 33: 137–164. doi:10.1615/CritRevImmunol.2013006813
- Browning, L., Patel, M.R., Horvath, E.B., Tawara, K., & Jorcyk, C.L., 2018. IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasis. *Cancer Manag. Res.* 10: 6685–6693. doi:10.2147/CMAR.S179189
- Bryant, A., Hiu, S., Kunonga, P.T., Gajjar, K., Craig, D., Vale, L., et al., 2022. Impact of residual disease as a prognostic factor for survival in women with

- advanced epithelial ovarian cancer after primary surgery. *Cochrane Database Syst. Rev.* 2022. doi:10.1002/14651858.CD015048.pub2
- Budiana, I.N.G., Angelina, M., & Pemayun, T.G.A., 2019. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J. Turkish Ger. Gynecol. Assoc.* 20: 41–46. doi:10.4274/jtgga.galenos.2018.2018.0039
- Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., et al., 2012. Incorporation of Bevacizumab in The Primary Treatment of Ovarian Cancer. *Obstet. Gynecol. Surv.* 67: 289–290. doi:10.1097/OGX.0b013e3182547170
- Cai, D.L., & Jin, L.-P., 2017. Immune Cell Population in Ovarian Tumor Microenvironment. *J. Cancer* 8: 2915–2923. doi:10.7150/jca.20314
- Cantón-Romero, J.C., Miranda-Díaz, A.G., Bañuelos-Ramírez, J.L., Carrillo-Ibarra, S., Sifuentes-Franco, S., Castellanos-González, J.A., et al., 2017. Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer. *Oxid. Med. Cell. Longev.* 2017. doi:10.1155/2017/2873030
- Castells, M., Thibault, B., Delord, J.P., & Couderc, B., 2012. Implication of tumor microenvironment in chemoresistance: Tumor-associated stromal cells protect tumor cells from cell death. *Int. J. Mol. Sci.* doi:10.3390/ijms13089545
- Chan, J.K., Urban, R., Cheung, M.K., Osann, K., Husain, A., Teng, N.N., et al., 2006. Ovarian cancer in younger vs older women: A population-based analysis. *Br. J. Cancer* 95: 1314–1320. doi:10.1038/sj.bjc.6603457
- Chang, L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L.L., & Cheng, W.F., 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS One* 13: 1–11. doi:10.1371/journal.pone.0194993
- Chen, C.A., Cheng, W.F., Lee, C.N., Chen, T.M., Kung, C.C.S., Hsieh, F.J., et al., 1999. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival. *Gynecol. Oncol.* 74: 235–240. doi:10.1006/gyno.1999.5418

- Chen, D.S., & Mellman, I., 2013. Oncology meets immunology: The cancer-immunity cycle. *Immunity*. doi:10.1016/j.immuni.2013.07.012
- Chen, G., Zhu, L., Yang, Y., Long, Y., Li, X., & Wang, Y., 2018. Prognostic role of neutrophil to lymphocyte ratio in ovarian cancer: A meta-analysis. *Technol. Cancer Res. Treat.* 17: 1–8. doi:10.1177/1533033818791500
- Chen, M., Jin, Y., Bi, Y., Li, Y., Shan, Y., & Pan, L., 2015. Prognostic significance of lymphovascular space invasion in epithelial ovarian cancer. *J. Cancer* 6: 412–419. doi:10.7150/jca.11242
- Chen, Y.L., Cheng, W.F., Chang, M.C., Lin, H.W., Huang, C.T., Chien, C.L., et al., 2013. Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. *Gynecol. Oncol.* 131: 63–68. doi:10.1016/j.ygyno.2013.07.105
- Chen, Y.L., Chou, C.Y., Chang, M.C., Lin, H.W., Huang, C.T., Hsieh, S.F., et al., 2015. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients. *Endocr. Relat. Cancer* 22: 703–711. doi:10.1530/ERC-15-0145
- Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D.A., et al., 2011. Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. *Clin. Cancer Res.* 17: 6083–6096. doi:10.1158/1078-0432.CCR-11-0945
- Dalal, V., Kumar, R., Kumar, S., Sharma, A., Kumar, L., Sharma, J.B., et al., 2018. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. *Clin. Chim. Acta* 482: 27–32. doi:10.1016/j.cca.2018.03.019
- Darb-Esfahani, S., Kunze, C.A., Kulbe, H., Sehouli, J., Wienert, S., Lindner, J., et al., 2015. Prognostic Impact of Programmed Cell Death-1 ( PD-1 ) and PD-Ligand 1 ( PD-L1 ) Expression in Cancer Cells and Tumor Infiltrating Lymphocytes in Ovarian High Grade Serous Carcinoma. *Oncotarget* 7: 1486–1499.
- Drakes, M.L., & Stiff, P.J., 2018. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. *Cancers (Basel)*. 10. doi:10.3390/cancers10090302
- Dunn, G.P., Bruce, A.T., Sheehan, K.C.F., Shankaran, V., Uppaluri, R., Bui, J.D.,

- et al., 2005. A critical function for type I interferons in cancer immunoediting. *Nat. Immunol.* 6: 722–729. doi:10.1038/ni1213
- Ezzati, M., Abdullah, A., Shariftabrizi, A., Hou, J., Kopf, M., Stedman, J.K., et al., 2014. Recent advancements in prognostic factors of epithelial ovarian carcinoma. *ISRN Obstet. Gynecol.* doi:10.1155/2014/953509
- Fahmi, M.N., Pradjatmo, H., Astuti, I., & Nindrea, R.D., 2021. Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis. *Asian Pacific J. Cancer Prev.* 22: 315–323. doi:10.31557/APJCP.2021.22.2.315
- Fanale, D., Dimino, A., Pedone, E., Brando, C., Corsini, L.R., Filorizzo, C., et al., 2022. Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. *Cancers (Basel)*. 14: 1–16. doi:10.3390/cancers14184344
- Folkman, J., 2003. Angiogenesis and Apoptosis. *Semin. Cancer Biol.* 13: 159–167. doi:10.1016/S1044-579X(02)00133-5
- Freedman, L.S., 1982. Tables of the number of patients required in clinical trials using the logrank test. *Stat. Med.* 1: 121–129. doi:10.1002/sim.4780010204
- Freedman, R.S., Kudelka, A.P., Kavanagh, J.J., Verschraegen, C., Edwards, C.L., Nash, M., et al., 2000. Clinical and biological effects of intraperitoneal injections of recombinant interferon- $\gamma$  and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. *Clin. Cancer Res.* 6: 2268–2278.
- Fujita, K., Ikarashi, H., Takakuwa, K., Kodama, S., Tokunaga, A., Takahashi, T., et al., 1995. Prolonged Disease-free Period in Patients with Advanced Epithelial Ovarian Cancer after Adoptive Transfer of Tumor-infiltrating Lymphocytes<sup>1</sup>, *Clinical Cancer Research*.
- Gasparri, M.L., Attar, R., Palaia, I., Perniola, G., Marchetti, C., Donato, V. Di, et al., 2015. Tumor Infiltrating Lymphocytes in Ovarian Cancer. *Asian Pacific J. Cancer Prev.* 16: 3635–3638. doi:10.7314/APJCP.2015.16.9.3635
- Gavalas, N.G., Lontos, M., Trachana, S.P., Bagratuni, T., Arapinis, C., Liacos, C., et al., 2013. Angiogenesis-related pathways in the pathogenesis of ovarian

cancer. *Int. J. Mol. Sci.* doi:10.3390/ijms140815885

Gawrychowski, K., Szewczyk, G., Skopińska-Różewska, E., Małecki, M., Barcz, E., Kamiński, P., et al., 2014. The angiogenic activity of ascites in the course of ovarian cancer as a marker of disease progression. *Dis. Markers* 1–5. doi:10.1155/2014/683757

Geomini, P., Kruitwagen, R., Bremer, G.L., Cnossen, J., & Mol, B.W.J., 2009. The accuracy of risk scores in predicting ovarian malignancy: A systematic review. *Obstet. Gynecol.* 113: 384–394. doi:10.1097/AOG.0b013e318195ad17

Ghoneum, A., Afify, H., Salih, Z., Kelly, M., & Said, N., 2018. Role of tumor microenvironment in ovarian cancer pathobiology. *Oncotarget* 9: 22832–22849. doi:10.18632/oncotarget.25126

Gonzalez, H., Hagerling, C., & Werb, Z., 2018. Roles of the immune system in cancer: From tumor initiation to metastatic progression. *Genes Dev.* 32: 1267–1284. doi:10.1101/GAD.314617.118

Gupta, D., & Lis, C.G., 2009. Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature. *J. Ovarian Res.* 2: 1–20. doi:10.1186/1757-2215-2-13

Gupta, M., Babic, A., Beck, A.H., & Terry, K., 2016. TNF- $\alpha$  expression, risk factors, and inflammatory exposures in ovarian cancer: Evidence for an inflammatory pathway of ovarian carcinogenesis? *Hum. Pathol.* 54: 82–91. doi:10.1016/j.humpath.2016.03.006

Hendry, S., Salgado, R., Gevaert, T., Russell, P.A., John, T., Thapa, B., et al., 2017. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinom. *Adv. Anat. Pathol.* 24: 311–335. doi:10.1097/PAP.0000000000000161

Hisamatsu, T., Mabuchi, S., Sasano, T., Kuroda, H., Takahashi, R., Matsumoto, Y., et al., 2015. The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer. *Clin. Exp. Metastasis* 32: 789–798. doi:10.1007/s10585-015-9751-0

- Hsieh, S.F., Lau, H.Y., Wu, H.H., Hsu, H.C., Twu, N.F., & Cheng, W.F., 2019. Prognostic factors of early stage epithelial ovarian carcinoma. *Int. J. Environ. Res. Public Health* 16: 1–12. doi:10.3390/ijerph16040637
- Huang, Q.-T., Zhong, M., Zhou, L., Zeng, W.-J., Ma, Q.-Q., Wang, W., et al., 2017. Prognostic Significance of Neutrophil-to- Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies. *Cell Physiol Biochem* 41: 2411–2418. doi:10.1159/000475911
- Hwang, C., Lee, S.J., Lee, J.H., Kim, K.H., Suh, D.S., Kwon, B.S., et al., 2019. Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. *Oncol. Lett.* 17: 4557–4565. doi:10.3892/ol.2019.10095
- Hwang, W.T., Adams, S.F., Tahirovic, E., Hagemann, I.S., & Coukos, G., 2012. Prognostic Significance of Tumor Infiltrating T cells in Ovarian Cancer: A Meta-Analysis. *Gynecol. Oncol.* 124: 192–198. doi:10.1016/j.ygyno.2011.09.039
- James, F.R., Jiminez-Linan, M., Alsop, J., Mack, M., Song, H., Brenton, J.D., et al., 2017. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. *BMC Cancer* 17: 1–7. doi:10.1186/s12885-017-3585-x
- Jochems, C., & Schlom, J., 2011. Between Conventional Cancer Therapy and Immunity. *J. Exp. Med.* 236: 567–579. doi:10.1258/ebm.2011.011007.Tumor-infiltrating
- Jones, V.S., Huang, R.Y., Chen, L.P., Chen, Z.S., Fu, L., & Huang, R.P., 2016. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. *Biochim. Biophys. Acta - Rev. Cancer* 1865: 255–265. doi:10.1016/j.bbcan.2016.03.005
- Kheiri, S.A., Kunna, A., Babiker, A.Y., Alsuhaibani, S.A., Ahmed, R.Y., & Alsammani, M.A., 2018. Histopathological pattern and age distribution, of malignant ovarian tumor among sudanese ladies. *Open Access Maced. J. Med. Sci.* 6: 237–241. doi:10.3889/OAMJMS.2018.067
- Kim, S., Kim, B., & Song, Y.S., 2016. Ascites modulates cancer cell behavior,



- contributing to tumor heterogeneity in ovarian cancer. *Cancer Sci.* 107: 1173–1178. doi:10.1111/cas.12987
- Kim, S.J., Rosen, B., Fan, I., Ivanova, A., McLaughlin, J.R., Risch, H., et al., 2017. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. *Br. J. Cancer* 116: 964–971. doi:10.1038/bjc.2017.35
- Kolomeyevskaya, N., Eng, K.H., Khan, A.N.H., Grzankowski, K.S., Singel, K.L., Moysich, K., et al., 2015. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor- $\alpha$  and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. *Gynecol. Oncol.* 138: 352–357. doi:10.1016/j.ygyno.2015.05.009
- Kurman, R.J., & Shih, I.M., 2016. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. *Am. J. Pathol.* 186: 733–747. doi:10.1016/j.ajpath.2015.11.011
- Lane, D., Matte, I., Garde-Granger, P., Bessette, P., & Piché, A., 2018. Ascites IL-10 Promotes Ovarian Cancer Cell Migration. *Cancer Microenviron.* 11: 115–124. doi:10.1007/s12307-018-0215-3
- Lane, D., Matte, I., Garde-Granger, P., Laplante, C., Carignan, A., Rancourt, C., et al., 2015. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. *BMC Cancer* 15: 1–11. doi:10.1186/s12885-015-1511-7
- Lane, D., Matte, I., Rancourt, C., & Piché, A., 2011. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. *BMC Cancer* 11. doi:10.1186/1471-2407-11-210
- Lee, L., Hellendall, R.P., Wang, Y., Haskill, J.S., Mukaida, N., Matsushima, K., et al., 2000. IL-8 Reduced Tumorigenicity of Human Ovarian Cancer In Vivo Due to Neutrophil Infiltration. *J. Immunol.* 164: 2769–2775. doi:10.4049/jimmunol.164.5.2769
- Li, J., Wang, J., Chen, R., Bai, Y., & Lu, X., 2017. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. *Oncotarget* 8: 15621–15631. doi:10.18632/oncotarget.14919



- Li, Y.L., Zhao, H., & Ren, X.B., 2016. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? *Cancer Biol. Med.* 13: 206–214. doi:10.20892/j.issn.2095-3941.2015.0070
- Li, Z., Yin, H., Ren, M., & Shen, Y., 2020. Prognostic significance of CA125 dynamic change for progression free survival in patients with epithelial ovarian carcinoma. *Med. Sci. Monit.* 26: 1–8. doi:10.12659/MSM.925051
- Liang, B., Guo, Z., Li, Y., & Liu, C., 2013. Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer. *Scand. J. Clin. Lab. Invest.* 73: 309–314. doi:10.3109/00365513.2013.773593
- Ligament, B., 2018. Special Section : Ovarian Cancer. *Am. Cancer Soc.* 45: 28–43.
- Markmann, S., Gerber, B., & Briese, V., 2007. Prognostic value of Ca 125 levels during primary therapy. *Anticancer Res.* 27: 1837–1839.
- Masoumi Moghaddam, S., Amini, A., Morris, D.L., & Pourgholami, M.H., 2012. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. *Cancer Metastasis Rev.* doi:10.1007/s10555-011-9337-5
- Matsuo, K., Hasegawa, K., Yoshino, K., Murakami, R., Hisamatsu, T., Stone, R.L., et al., 2015. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. *Eur. J. Cancer* 51: 1978–1988. doi:10.1016/j.ejca.2015.07.012
- Matsuo, K., Yoshino, K., Hiramatsu, K., Banzai, C., Hasegawa, K., Yasuda, M., et al., 2014. Effect of Lymphovascular Space Invasion on Survival of Stage I Epithelial Ovarian Cancer. *Obstet. Gynecol.* 123: 957–965. doi:10.1097/AOG.0000000000000240
- Matte, I., Lane, D., Laplante, C., Rancourt, C., & Piché, A., 2012. Profiling of cytokines in human epithelial ovarian cancer ascites. *Am. J. Cancer Res.* 2: 566–80.
- Minor, D.R., Moores, S.P., & Chan, J.K., 2017. Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer. *Gynecol. Oncol. Reports* 22: 43–44. doi:10.1016/j.gore.2017.09.009
- Monk, B.J., Brady, M.F., Aghajanian, C., Lankes, H.A., Rizack, T., Leach, J., et

- al., 2017. A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of Chemoimmunotherapy Combination using Motolimod with Pegylated Liposomal Doxorubicin in Recurrent or Persistent Ovarian Cancer: A Gynecologic Oncology Group partners study. *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.* 28: 996–1004. doi:10.1093/annonc/mdx049
- Musrap, N., & Diamandis, E.P., 2012. Revisiting the Complexity of the Ovarian Cancer Microenvironment--Clinical Implications for Treatment Strategies. *Mol. Cancer Res.* 10: 1254–1264. doi:10.1158/1541-7786.MCR-12-0353
- Nash, M.A., Ferrandina, G., Gordinier, M., Loercher, A., & Freedman, R.S., 1999. The role of cytokines in both the normal and malignant ovary. *Endocr. Relat. Cancer* 6: 93–107. doi:10.1677/erc.0.0060093
- National Collaborating Centre, 2011. Ovarian cancer: The recognition and initial management of ovarian cancer. *Heal. (San Fr. NICE clini.*
- Nelson Brad H, 2008. The Impact of T-Cell Immunity on Ovarian Cancer Outcomes.
- O'Toole, S.A., Sheppard, B.L., Laios, A., O'Leary, J.J., McGuinness, E.P.J., D'Arcy, T., et al., 2007. Potential predictors of chemotherapy response in ovarian cancer-How do we define chemosensitivity? *Gynecol. Oncol.* 104: 345–351. doi:10.1016/j.ygyno.2006.08.039
- Oge, T., Ozalp, S.S., & Yalcin, O.T., 2011. Prognostic Factors In Epithelial Ovarian Carcinoma: A Reference Institution Experience. *J. Turkish Soc. Obstet. Gynecol.* 8: 51–56. doi:10.5505/tjod.2011.05902
- Öge, T., Özalp, S.S., & Yalçın, Ö.T., 2011. Prognostic factors in epithelial ovarian carcinoma: A reference institution experience. *Turk Jinekoloji ve Obstet. Dern. Derg.* 8: 51–56. doi:10.5505/tjod.2011.05902
- Paoletti, X., Lewsley, L.A., Daniele, G., Cook, A., Yanaihara, N., Tinker, A., et al., 2020. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis. *JAMA Netw. Open* 3: 1–15. doi:10.1001/jamanetworkopen.2019.18939
- Paradkar, P.H., Joshi, J.V., Mertia, P.N., Agashe, S.V., & Vaidya, R.A., 2014. Role

- of cytokines in genesis, progression and prognosis of cervical cancer. *Asian Pacific J. Cancer Prev.* doi:10.7314/APJCP.2014.15.9.3851
- Parveen, A., Subedi, L., Kim, H., Khan, Z., Zahra, Z., Farooqi, M., et al., 2019. Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy. *J. Clin. Med.* 8: 350. doi:10.3390/jcm8030350
- Paul, M.S., Saibil, S.D., Lien, S.C., Han, S.J., Sayad, A., Mulder, D.T., et al., 2020. IL6 induces an IL22+ CD8+ T-cell subset with potent antitumor function. *Cancer Immunol. Res.* 8: 321–333. doi:10.1158/2326-6066.CIR-19-0521
- Peres, L.C., Cushing-Haugen, K.L., Köbel, M., Harris, H.R., Berchuck, A., Rossing, M.A., et al., 2019. Invasive epithelial ovarian cancer survival by histotype and disease stage. *J. Natl. Cancer Inst.* 111. doi:10.1093/jnci/djy071
- Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., et al., 2011. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. *N. Engl. J. Med.* 365: 2484–2496. doi:10.1056/nejmoa1103799
- Prat, J., & Committee, F., 2014. International Journal of Gynecology and Obstetrics Staging classification for cancer of the ovary, fallopian tube, and peritoneum ☆. *Int. J. Gynecol. Obstet.* 124: 1–5. doi:10.1016/j.ijgo.2013.10.001
- Qian, X., Xi, X., & Jin, Y., 2010. The grading of lymphovascular space invasion in epithelial ovarian carcinoma. *Int. J. Gynecol. Cancer* 20: 895–899. doi:10.1111/IGC.0b013e3181e02fc7
- Rao, U.N.M., Lee, S.J., Luo, W., Mihm, M.C., & Kirkwood, J.M., 2010. Presence of Tumor-Infiltrating Lymphocytes and A Dominant Nodule Within Primary Melanoma are Prognostic Factors for Relapse-Free Survival of Patients with Thick (T4) Primary Melanoma: Pathologic Analysis of The E1690 and E1694 Intergroup Trials. *Am. J. Clin. Pathol.* 133: 646–653. doi:10.1309/AJCPTXMEFOVYWDA6
- Rodriguez, G.M., Galpin, K.J.C., McCloskey, C.W., & Vanderhyden, B.C., 2018. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. *Cancers (Basel)*. doi:10.3390/cancers10080242
- Rosenberg, S.A., Lotze, M.T., Yang, J.C., Aebersold, P.M., Linehan, W.M., Seipp, C.A., et al., 1989. Experience with the Use of High-Dose Interleukin-2 in the

- Treatment of 652 Cancer Patients. *Ann. Surg.* 210: 474–485.  
doi:10.1097/00000658-198910000-00008
- Rudlowski, C., Pickart, A.K., Fuhljahn, C., Friepoertner, T., Schlehe, B., Biesterfeld, S., et al., 2006. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: A long-term follow-up. *Int. J. Gynecol. Cancer* 16: 183–189. doi:10.1111/j.1525-1438.2006.00307.x
- Rustin, G.J.S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., et al., 2011. Definitions for response and progression in ovarian cancer clinical trials incorporating recist 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). *Int. J. Gynecol. Cancer* 21: 419–423. doi:10.1097/IGC.0b013e3182070f17
- Saad, A.F., Hu, W., & Sood, A.K., 2010. Microenvironment and Pathogenesis of Epithelial Ovarian Cancer. *Horm. Cancer* 1: 277–290. doi:10.1007/s12672-010-0054-2
- Saito, T., Berens, M.E., & Welandar, C.E., 1987. Interferon-gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay. *Cancer Chemother. Pharmacol.* 19: 233–239. doi:10.1007/BF00252978
- Santoemma, P.P., & Powell, D.J., 2015. Tumor infiltrating lymphocytes in ovarian cancer. *Cancer Biol. Ther.* 16: 807–820. doi:10.1080/15384047.2015.1040960
- Savant, S.S., Sriramkumar, S., & O'Hagan, H.M., 2018. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. *Cancers (Basel)*. 10. doi:10.3390/cancers10080251
- Scambia, G., Testa, U., Panici, P.B., Foti, E., Martucci, R., Gadducci, A., et al., 1995. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. *Br. J. Cancer* 71: 354–356. doi:10.1038/bjc.1995.71
- Schauer, I.G., Zhang, J., Xing, Z., Guo, X., Mercado-Urbe, I., Sood, A.K., et al., 2013a. Interleukin-1  $\beta$  Promotes Ovarian Tumorigenesis through a p53 / NF- $\kappa$  B – Mediated Inflammatory Response in. *Neoplasia* 15: 409–420.

doi:10.1593/neo.121228

Schauer, I.G., Zhang, J., Xing, Z., Guo, X., Mercado-Urbe, I., Sood, A.K., et al., 2013b. Interleukin-1 $\beta$  promotes ovarian tumorigenesis through a p53/NF- $\kappa$ B-mediated inflammatory response in stromal fibroblasts. *Neoplasia (United States)* 15: 409–420. doi:10.1593/neo.121228

Siegel, R.L., Miller, K.D., & Jemal, A., 2019. Cancer statistics, 2019 (US statistics). *CA. Cancer J. Clin.* 69: 7–34. doi:10.3322/caac.21551

Strandmann, E.P. von, Reinartz, S., Wager, U., & Müller, R., 2017. Tumor–Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure. *Trends in Cancer* 3: 137–148. doi:10.1016/j.trecan.2016.12.005

Szlosarek, P.W., Grimshaw, M.J., Kulbe, H., Wilson, J.L., Wilbanks, G.D., Burke, F., et al., 2006. Expression and regulation of tumor necrosis factor  $\alpha$  in normal and malignant ovarian epithelium. *Mol. Cancer Ther.* 5: 382–390. doi:10.1158/1535-7163.MCT-05-0303

Szulc-Kielbik, I., Kielbik, M., Nowak, M., & Klink, M., 2021. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. *Biochim. Biophys. Acta - Rev. Cancer* 1876: 188639. doi:10.1016/j.bbcan.2021.188639

Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E., 2018. Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. *Medicines* 5: 16. doi:10.3390/medicines5010016

Tjokroprawiro, B.A., Fadli, S., & Budiono, B., 2021. Evaluating the Association between Clinical Characteristics with Progression-Free Survival and 3-Year Survival in Patients with Epithelial Ovarian Cancer. *Indones. J. Cancer* 15: 162. doi:10.33371/ijoc.v15i4.815

Trachana, S., Pilalis, E., Gavalas, N.G., & Tzannis, K., 2016. The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling 1–16. doi:10.1371/journal.pone.0156403

Van Der Zee, A.G.J., De Bruijn, H.W.A., Krans, M., De Cuyper, E.M.J., Hollema,

- H., Limburg, P.C., et al., 1995. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. *Cancer* 75: 1004–1009. doi:10.1002/1097-0142(19950215)75:4<1004::AID-CNCR2820750416>3.0.CO;2-G
- Wall, L., Burke, F., Barton, C., Smyth, J., & Balkwill, F., 2003. IFN- $\gamma$  induces apoptosis in ovarian cancer cells in vivo and in vitro. *Clin. Cancer Res.* 9: 2487–2496.
- Wang, Y., Van Boxel-Dezaire, A.H.H., Cheon, H., Yang, J., & Stark, G.R., 2013. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. *Proc. Natl. Acad. Sci. U. S. A.* 110: 16975–16980. doi:10.1073/pnas.1315862110
- Webb, P.M., & Jordan, S.J., 2017. Epidemiology of epithelial ovarian cancer. *Best Pract. Res. Clin. Obstet. Gynaecol.* doi:10.1016/j.bpobgyn.2016.08.006
- Winter, W.E., Maxwell, G.L., Tian, C., Carlson, J.W., Ozols, R.F., Rose, P.G., et al., 2007. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. *J. Clin. Oncol.* 25: 3621–3627. doi:10.1200/JCO.2006.10.2517
- Woolery, K.T., & Kruk, P.A., 2011. Ovarian Epithelial-Stromal Interactions: Role of Interleukins 1 and 6. *Obstet. Gynecol. Int.* 2011: 1–9. doi:10.1155/2011/358493
- Worzfeld, T., von Strandmann, E.P., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., et al., 2017. The unique molecular and cellular microenvironment of Ovarian cancer. *Front. Oncol.* 7. doi:10.3389/fonc.2017.00024
- Wu, L., Deng, Z., Peng, Y., Han, L., & Liu, J., 2017. Ascites-derived IL-6 and IL-10 synergistically expand 8: 76843–76856.
- Yeung, T.L., Leung, C.S., Yip, K.P., Yeung, C.L.A., Wong, S.T.C., & Mok, S.C., 2015. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: Cell and molecular processes in cancer metastasis. *Am. J. Physiol. - Cell Physiol.* 309: C444–C456. doi:10.1152/ajpcell.00188.2015
- Yin, X., Wu, L., Yang, Hui, & Yang, Hongbo, 2019. Prognostic significance of

neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer. *Medicine (Baltimore)*. 98: e17475. doi:10.1097/MD.00000000000017475

Yuan, Y., Jiang, Y.C., Sun, C.K., & Chen, Q.M., 2016. Role of the tumor microenvironment in tumor progression and the clinical applications (Review). *Oncol. Rep.* 35: 2499–2515. doi:10.3892/or.2016.4660

Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., Regnani, G., et al., 2003. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. *N. Engl. J. Med.* 348: 203–213. doi:10.1056/NEJMoa020177

Zhang, Y.-L., Li, J., Mo, H.-Y., Qiu, F., Zheng, L.-M., Qian, C.-N., et al., 2010. Different Subsets of Tumor Infiltrating Lymphocytes Correlate with NPC Progression in Different Ways.

Zhou, J., & Brune, B., 2006. Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1 $\alpha$ ; (HIF-1 $\alpha$ ). *Cardiovasc. Hematol. Agents Med. Chem.* 4: 189–197. doi:10.2174/187152506777698344